A Welcome Signal for Millions on Weight-Loss Drugs
Diabetic retinopathy is the leading cause of vision loss among working-age adults, affecting roughly one in three people with diabetes. As GLP-1 receptor agonists and dual-incretin drugs have surged in popularity for weight management and blood sugar control, a pressing question has hung over the field: could these medications affect the eyes? A large retrospective study from Weill Cornell Medicine now provides reassuring news, at least for tirzepatide.
Published in Ophthalmology, the analysis examined electronic health records from approximately 174,000 patients across 70 U.S. health systems. Patients who initiated tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management, were compared against matched controls receiving only lifestyle interventions such as nutrition therapy or exercise counseling. The results showed significantly lower rates of new-onset and worsening diabetic retinopathy among tirzepatide users.
Key Findings
Lead author Dr. Szilard Kiss reports that mild non-proliferative diabetic retinopathy, the earliest stage of the disease, occurred in just 0.49 percent of tirzepatide users over 12 months, compared to 1.2 percent of controls. That translates to a roughly 60 percent relative risk reduction.
The benefits extended to more advanced forms of the disease. Tirzepatide users also showed lower 12-month rates of proliferative diabetic retinopathy, in which abnormal blood vessels grow on the retina, and of diabetic macular edema, a condition in which fluid leaks into the central retina and blurs vision. Patients on tirzepatide were also less likely to experience vitreous hemorrhage, bleeding into the gel-filled center of the eye, or tractional retinal detachment, in which scar tissue pulls the retina away from its supporting layer.
Fewer Eye Procedures Needed
Beyond disease incidence, the study found that tirzepatide users required fewer eye interventions, including intravitreal injections and laser photocoagulation, the two mainstays of diabetic retinopathy treatment. These procedures are effective but burdensome, requiring repeated clinic visits and carrying their own risks. Any reduction in their necessity represents a meaningful improvement in patient quality of life.
